WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: 'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval — Warptech Lab News

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 20 fonti

'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval

RAS inhibitor daraxonrasib doubled survival outcomes in second-line trial

Raccontata da

medpagetoday.com

jpost.com+8 altre

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo16 h fa

'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval

RAS inhibitor daraxonrasib doubled survival outcomes in second-line trial

Timeline cronologica

mercoledì 26 agosto 2026·forbes.com
FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque
Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.
mercoledì 26 agosto 2026·healio.com
Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma
The FDA has approved a first-in-class targeted therapy for adults with metastatic pancreatic adenocarcinoma. Daraxonrasib (Rasonque, Revolution Medicines), an RAS inhibitor,…

11 h fa

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA approves Revolution Medicines' daraxonrasib (Rasonque) for second-line pancreatic cancer, after it nearly doubled survival in a Phase 3 to 13.2 months vs. 6.7 months on chemo.

Leggi questa versione → originale

healio.com1 g fa

Rasonque nabs FDA approval for previously treated metastatic pancreatic adenocarcinoma

The FDA has approved a first-in-class targeted therapy for adults with metastatic pancreatic adenocarcinoma. Daraxonrasib (Rasonque, Revolution Medicines), an RAS inhibitor, received approval for patients who previously…

Leggi questa versione → originale

qz.com8 h fa

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

The drug, Rasonque, nearly doubled median overall survival compared with standard chemotherapy in a 500-patient trial

Leggi questa versione → originale

forbes.com1 g fa

FDA Approves Pancreatic Cancer Drug That Could Double Survival Time—What To Know About Rasonque

Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.

Leggi questa versione → originale

hindustantimes.com2 h fa

Pancreatic cancer drug Daraxonrasib gets approval from FDA: All you need to know

FDA officials gave expedited approval to daraxonrasib, which blocks a mutated protein that fuels tumor growth

Leggi questa versione → originale

mercoledì 26 agosto 2026·

medpagetoday.com

'Grand Slam' Pancreatic Cancer Drug Wins FDA Approval

RAS inhibitor daraxonrasib doubled survival outcomes in second-line trial

mercoledì 26 agosto 2026·

apnews.com

FDA approves landmark pancreatic cancer drug that's shown to improve survival

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.

mercoledì 26 agosto 2026·

statnews.com

FDA approves new pancreatic cancer drug expected to usher in new era of treatment

The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.

mercoledì 26 agosto 2026·

endpoints.news

FDA approves Revolution Medicines' pancreatic cancer drug, ushering in new era of KRAS therapy

FDA approves Revolution Medicines' daraxonrasib (Rasonque) for second-line pancreatic cancer, after it nearly doubled survival in a Phase 3 to 13.2 months vs. 6.7 months on chemo.

mercoledì 26 agosto 2026·

abcnews.com

FDA approves breakthrough drug to treat advanced pancreatic cancer

The Food and Drug Administration approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer.

mercoledì 26 agosto 2026·

cnn.com

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | CNN

The U.S. Food and Drug Administration on Wednesday approved Revolution Medicines’ targeted drug for adults with metastatic pancreatic cancer who have received prior treatment or…

mercoledì 26 agosto 2026·

cnbc.com

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug

The drug is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many pancreatic cancers.

mercoledì 26 agosto 2026·

thestar.com

FDA approves landmark pancreatic cancer drug that’s shown to improve survival

WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for the most common form of pancreatic cancer, offering U.S. patients a more…

mercoledì 26 agosto 2026·

lasicilia.it

Tumore del pancreas, via libera negli Usa alla prima terapia mirata contro il gene killer RAS

L'approvazione di daraxonrasib apre una nuova era nell'oncologia di precisione per i pazienti più difficili da trattare

mercoledì 26 agosto 2026·

jpost.com

Revolution Medicines gets FDA nod for targeted pancreatic cancer drug | The Jerusalem Post

The drug, branded as Rasonque and also known as daraxonrasib, is a once-daily pill designed to block several forms of the RAS protein, which helps drive tumor growth in many…

mercoledì 26 agosto 2026·

independent.co.uk

New hope for pancreatic cancer patients after FDA approves drug to improve survival

Pancreatic cancer is among the deadliest forms, largely because detection is difficult before malignancy spreads to other organs

mercoledì 26 agosto 2026·

nbcnews.com

FDA approves ‘game-changing’ pancreatic cancer drug

In a late-stage trial, people who got Revolution Medicines’ Rasonque, or daraxonrasib, lived about twice as long as people who got standard care.

mercoledì 26 agosto 2026·

qz.com

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

The drug, Rasonque, nearly doubled median overall survival compared with standard chemotherapy in a 500-patient trial

mercoledì 26 agosto 2026·

benzinga.com

Revolution Medicines Wins FDA Nod for First-Of-Its-Kind Pancreatic Cancer Drug - Revolution Medicines (NA

FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancer. Phase 3 trials show a 60% reduced death risk vs chemotherapy.

mercoledì 26 agosto 2026·

ilfattoquotidiano.it

Tumore al pancreas: nuovo trattamento in compresse raddoppia la sopravvivenza

La FDA ha approvato daraxonrasib per il cancro al pancreas metastatico: 13,2 mesi di sopravvivenza contro 6,7 della chemio.

mercoledì 26 agosto 2026·

huffpost.com

FDA Approves Landmark Pancreatic Cancer Drug That's Shown To Improve Survival

U.S. health officials have approved a groundbreaking pancreatic cancer drug that offers a new approach to treating the deadly form of cancer.

mercoledì 26 agosto 2026·

washingtonexaminer.com

FDA approves breakthrough pancreatic cancer drug proven to extend survival

Former Nebraska Sen. Ben Sasse credited the drug with extending his life after his terminal cancer diagnosis.

giovedì 27 agosto 2026·

cbsnews.com

FDA approves new pancreatic cancer drug that could extend patients' lives

Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.